Glenmark Pharmaceuticals Limited
GLENMARK
Clasificación en acciones
#2736
Glenmark Pharmaceuticals Limited, including its associated entities, is a... Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
Precio por acción
$24.39
Última sincronización: 2026-10-19
Capitalización bursátil
$6.88B
Cambio (1 día)
-1.20%
Cambio (1 año)
15.69%
País
IN
Comercio Glenmark Pharmaceuticals Limited (GLENMARK)
Categoría
Healthcare
Historial de dividendos de Glenmark Pharmaceuticals Limited (GLENMARK)
Glenmark Pharmaceuticals Limited (símbolo bursátil: GLENMARK) realizó un total de 25 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: $38.40
Rentabilidad por dividendo (TTM): 0.0022
La suma de todos los dividendos (ajustados por splits de acciones) es: $38.40
Rentabilidad por dividendo (TTM): 0.0022
Pagos de dividendos de Glenmark Pharmaceuticals Limited (GLENMARK) desde 2002 hasta 2026
Pagos anuales de dividendos
| Año | Dividendo (ajustado por splits de acciones) | Cambiar |
|---|---|---|
| 2026 (TTM) | $2.50 | -50.00% |
| 2025 | $5.00 | 100.00% |
| 2024 | $2.50 | 0.00% |
| 2023 | $2.50 | 0.00% |
| 2022 | $2.50 | 0.00% |
| 2021 | $2.50 | 0.00% |
| 2020 | $2.50 | 25.00% |
| 2019 | $2.00 | 0.00% |
| 2018 | $2.00 | 0.00% |
| 2017 | $2.00 | 0.00% |
| 2016 | $2.00 | 0.00% |
| 2015 | $2.00 | 0.00% |
| 2014 | $2.00 | 0.00% |
| 2013 | $2.00 | 0.00% |
| 2012 | $2.00 | 400.00% |
| 2011 | $0.4 | 0.00% |
| 2010 | $0.4 | 0.00% |
| 2009 | $0.4 | -63.64% |
| 2007 | $1.10 | 214.29% |
| 2006 | $0.35 | 0.00% |
| 2005 | $0.35 | -46.15% |
| 2004 | $0.65 | 0.00% |
| 2003 | $0.65 | 8.33% |
| 2002 | $0.6 | 0.00% |
Lista de todos los pagos de dividendos
| Año | Dividendo | Cambiar |
|---|---|---|
| 2026 (TTM) | $2.50 | -50.00% |
| 2025 | $5.00 | 100.00% |
| 2024 | $2.50 | 0.00% |
| 2023 | $2.50 | 0.00% |
| 2022 | $2.50 | 0.00% |
| 2021 | $2.50 | 0.00% |
| 2020 | $2.50 | 25.00% |
| 2019 | $2.00 | 0.00% |
| 2018 | $2.00 | 0.00% |
| 2017 | $2.00 | 0.00% |
| 2016 | $2.00 | 0.00% |
| 2015 | $2.00 | 0.00% |
| 2014 | $2.00 | 0.00% |
| 2013 | $2.00 | 0.00% |
| 2012 | $2.00 | 400.00% |
| 2011 | $0.4 | 0.00% |
| 2010 | $0.4 | 0.00% |
| 2009 | $0.4 | -73.33% |
| 2007 | $1.50 | 114.29% |
| 2006 | $0.7 | 0.00% |
| 2005 | $0.7 | -73.08% |
| 2004 | $2.60 | -80.00% |
| 2003 | $13.00 | 8.33% |
| 2002 | $12.00 | 0.00% |
Pagos de dividendos de empresas similares o competidoras
| Empresa | Número de pagos de dividendos | País |
|---|---|---|
| 0.00% |
DE
|
|
| 0.00% |
DE
|
|
| 0.00% |
JP
|
|
| 0.00% |
CH
|
|
| 38.00% |
IN
|
